NASDAQ:KALA 4 December 2025 - 5 December 2025

KALA BIO, Inc. has turned into one of the most volatile biotech penny stocks on the market in late 2025. After a failed eye‑disease trial, a loan default and a near‑miss with foreclosure, the company is now trying to recapitalize itself with fresh equity and new leadership. On December 4, 2025, KALA BIO announced a $10 million registered direct offering of common stock at $1.00 per share, the latest in a series of emergency financings and debt negotiations that have whipsawed KALA stock and left existing shareholders heavily diluted. Finviz+4GlobeNewswire+4GlobeNewswire+4

As of December 4, 2025, KALA BIO, Inc. has turned into one of the wildest tickers on the Nasdaq. The stock is trading around $1.40 in heavy volume, up roughly 50% on the day after a cascade of news: a $10 million registered direct offering, a loan settlement that turns lender Oxford Finance into a 16.5% shareholder, and a $6 million rescue-style preferred investment from new CEO David Lazar. All this arrives barely two months after KALA’s lead drug failed a key trial, its lender swept most of its cash, and management warned of “substantial doubt” about its ability to survive as a going concern. GlobeNewswire+3Stock Titan+3Stock Titan+3 This article pulls together the current news, forecasts and analyses as of December 4, 2025, and explains what they might mean for KALA stock.